Continuous adoption of biomarker testing in the diagnosis of lung cancer to remain a crucial growth attribute.
DUBAI, UAE / ACCESSWIRE / October 20, 2020 / The pd l1 biomarker testing market is showing a positive growth trajectory due to accelerated tracking of diseases and their associated treatment. According to new research market for PDL1 biomarker testing market, conducted by Future Market Insights (FMI), adoption of PDL1 will remain strong in the US and Europe during the course of the forecast period.
"Market players are constantly focussing on cost-efficient devices and strategic planning to ensure regional and international presence. Manufacturers are also trying to direct their attention towards improving these products," says the FMI Analyst.
Request a report sample to gain more market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-5897
PDL1 Biomarker Testing Market - Important Highlights
- PD-L1 SP142 assay kits will account for half the market share in terms of value, owing to high efficiency in detecting cancer
- North America will remain a key region as it holds almost 50% of the overall market share in terms of value.
- Due to soaring prevalence of these diseases, non-small cell lung cancer and melanoma is likely to hold 50% of the market share.
PDL1 Biomarker Testing Market - Driving Factors
- Cancer diagnostic and analysis requires major testing to detect early-stage non-small cell cancer.
- Use of PDL1 marker remains prominent in measuring treatment progress and acquiring better or accurate results.
- Adoption of PDL1 markers prove to highly efficient in revealing mutation and establishing protein expression levels to enhance cancer treatment.
- Lung cancer patients with adenocarcinoma rely on these testers to achieve early-stage progress and detection.
PDL1 Biomarker Testing Market - Key Restraints
- Poor efficiency and precision of biomarkers might hamper market growth to a great extent.
- Constant fluctuations in the result decelerates market growth and limit PDL1 adoption.
For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-5897
Anticipated Market Impact by Coronavirus Outbreak
The COVID-19 pandemic has had a considerable impact on PDL1 biomarker testing market. Reduced number of screenings is adversely affecting the market growth. According to Cancer Research Network, screening rate has decreased by 50% in UK and 30% in the United States.
However, considering the seriousness of these diseases, market will not remain sluggish for a long period and a recovery is expected in late 2021.
Competition Landscape
Key players in the market include F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., NeoGenomics Laboratories, Inc, HalioDx and Abcam plc. Participants are focussing on reduction of operational costs and adoption of organic strategies.
Business strategies like capacity expansion and strategic partnerships will boost the market growth globally, thereby, enhancing geographical presence throughout. Mergers and acquisitions will lead to a better foothold too.
Buy Now@ https://www.futuremarketinsights.com/checkout/5897
More on the report
FMI market research report presents in-depth insights on PDL1 biomarker testing market. The foremost objective focusses on demand generators, and technological advancements in the market including instrument precision and services. The report brings to our notice about the leading manufacturers who are involved in the market, along with their detailed profiles.
Essential and up-to-date data information related to key market players are principally engaged in the production of inhibitors, have been brought with the help of a detailed dashboard view.
Explore Wide-ranging Coverage of FMI's Healthcare Landscape
Cardiac Bio Marker Diagnostic Test Market Find insights on In-depth market segmentation, historical, current and projected market size in terms of volume and value with details about industry trends and developments.
Breast Pumps Market FMI's report on Breast Pumps Market throws light on market trends, global market insights, data and assumptions.
Teleradiology Services Market Read an analysis on information according to market segments such as geographies, application and industry, trends etc.
About FMI
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/pd-l1-biomarker-testing-market
Press Release Source: https://www.futuremarketinsights.com/press-release/pd-l1-biomarker-testing-market
SOURCE: Future Market Insights
View source version on accesswire.com:
https://www.accesswire.com/611287/PDL1-Biomarker-Testing-Market-to-surpass-US-2-billion-by-2030--Future-Market-Insights
